The Rosalind Franklin Institute is national research institute, dedicated to developing new technologies to tackle important health research challenges. The spectrum of tools under development at the Franklin are individually extraordinary, but when combined at the Franklin's Hub, they allow us to develop tomorrow's healthcare innovations. Our technologies will enable the 'imaging of life in five dimensions' - that is, to see the molecules of life in the context of three-dimensional space, along with time and chemistry. We are currently focusing our multi-disciplinary research teams and technologies in development to the grand challenge problem of infection and the body's response to it. Such an institute has significant challenges when addressing the data and computation challenges that come with development of these next generation instruments, and this proposal looks to address the immediate challenges surrounding this and put the institutes data strategy on track to make the most of all the data collected at the Franklin. To make sure that this proposal is fit for purpose, and also delivering in value, the proposal was passed through 3 independent groups at the Franklin before submission (https://www.rfi.ac.uk/about/governance/): 1 Theme Advisory Panel (https://www.rfi.ac.uk/about/governance/theme-advisory-panels/) : This group looked to the proposal for technical suitability 2 - The Value for Money Panel : This group looked to the economic side of the proposal, and general structure of the proposal. 3 - RFI Board Ratification : The final approval to proceed came through the Franklin Board who had oversight of the previous panels information.

The Life Sciences sector forms a key part of the UK economy: it employs over 220,000 people, contributes significantly to GDP and UK balance of trade, and is crucial for developing leading-edge treatments for patients. It is underpinned by the UK's world-leading research base in the health and life sciences. Many key research breakthroughs are, in turn, enabled by advances in engineering and physical sciences (EPS) research - which provide ever more sophisticated instrumentation and methods to support the study of living organisms (from microbes to plants, animals and the human body) and biological processes (including both disease pathology and drug action). R&D across all parts of this ecosystem - from fundamental understanding to applied research to product development - is crucial for the delivery of long-term economic growth and continued advances in agriculture, food security, healthcare and public health. Historic models of innovation have often been linear, involving a degree of serendipity. Disruptive technologies and scientific breakthroughs will be accelerated if physical scientists, engineers, life scientists and industry work together, and at scale. This is the domain of the Rosalind Franklin Institute (RFI): with a focal point (Hub) at Harwell Science and Innovation Campus, linked to formal Spokes in leading HEIs across the UK, it will integrate complementary expertise from academia and industry to create a national centre of excellence for methods development at the convergence of the physical and life sciences. It will create high-value jobs, protect and attract inward investment, and drive long-term growth; and contribute to the delivery of the Government's innovation, industrial and regional strategies.

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

The genomics revolution has opened up the protein world for discovery research in medicine, biosciences and biotechnology. Interpreting and exploiting this information necessitates an understanding of how proteins function as part of complex and dynamic macro-molecular assemblies in cells. Single domain antibodies or nanobodies are powerful tools for tagging and tracking proteins and their interactions. They can lock proteins into specific shapes that makes it easier to study their structure. By making nanobody technology more widely available to the UK Biosciences research community, the Nanobody Discovery Hub project will help accelerate research into how proteins work and how this knowledge can be usefully applied in structural, cell and synthetic biology.

The Life Sciences sector forms a key part of the UK economy: it employs over 220,000 people, contributes significantly to GDP and UK balance of trade, and is crucial for developing leading-edge treatments for patients. It is underpinned by the UK's world-leading research base in the health and life sciences. Many key research breakthroughs are, in turn, enabled by advances in engineering and physical sciences (EPS) research - which provide ever more sophisticated instrumentation and methods to support the study of living organisms (from microbes to plants, animals and the human body) and biological processes (including both disease pathology and drug action). R&D across all parts of this ecosystem - from fundamental understanding to applied research to product development - is crucial for the delivery of long-term economic growth and continued advances in agriculture, food security, healthcare and public health. Historic models of innovation have often been linear, involving a degree of serendipity. Disruptive technologies and scientific breakthroughs will be accelerated if physical scientists, engineers, life scientists and industry work together, and at scale. This is the domain of the Rosalind Franklin Institute (RFI): with a focal point (Hub) at Harwell Science and Innovation Campus, linked to formal Spokes in leading HEIs across the UK, it will integrate complementary expertise from academia and industry to create a national centre of excellence for methods development at the convergence of the physical and life sciences. It will create high-value jobs, protect and attract inward investment, and drive long-term growth; and contribute to the delivery of the Government's innovation, industrial and regional strategies.